vs
Amphastar Pharmaceuticals, Inc.（AMPH）とIBEX Ltd（IBEX）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amphastar Pharmaceuticals, Inc.の直近四半期売上が大きい（$183.1M vs $164.2M、IBEX Ltdの約1.1倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 7.4%、差は5.9%）。IBEX Ltdの前年同期比売上増加率が高い（16.7% vs -1.8%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $-5.1M）。過去8四半期でIBEX Ltdの売上複合成長率が高い（13.8% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
IBEX 35はスペインの主要取引所であるマドリード証券取引所のベンチマーク株価指数です。1992年に設定され、スペイン証券市場グループBME傘下の取引所会社が計算・管理を担当しています。時価総額加重方式で算出され、マドリード証券取引所で流動性の高い上位35銘柄で構成され、年に2度構成銘柄の見直しが行われます。
AMPH vs IBEX — 直接比較
損益計算書 — Q4 FY2025 vs Q2 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $164.2M |
| 純利益 | $24.4M | $12.2M |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | 9.3% |
| 純利益率 | 13.3% | 7.4% |
| 売上前年比 | -1.8% | 16.7% |
| 純利益前年比 | -35.7% | 31.8% |
| EPS（希薄化後） | $0.51 | $0.83 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $164.2M | ||
| Q3 25 | $191.8M | $151.2M | ||
| Q2 25 | $174.4M | $147.1M | ||
| Q1 25 | $170.5M | $140.7M | ||
| Q4 24 | $186.5M | $140.7M | ||
| Q3 24 | $191.2M | $129.7M | ||
| Q2 24 | $182.4M | $124.5M | ||
| Q1 24 | $171.8M | $126.8M |
| Q4 25 | $24.4M | $12.2M | ||
| Q3 25 | $17.4M | $12.0M | ||
| Q2 25 | $31.0M | $9.6M | ||
| Q1 25 | $25.3M | $10.5M | ||
| Q4 24 | $38.0M | $9.3M | ||
| Q3 24 | $40.4M | $7.5M | ||
| Q2 24 | $37.9M | $9.8M | ||
| Q1 24 | $43.2M | $10.3M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 9.3% | ||
| Q3 25 | 13.2% | 9.1% | ||
| Q2 25 | 24.2% | 8.3% | ||
| Q1 25 | 21.9% | 9.5% | ||
| Q4 24 | 24.2% | 8.5% | ||
| Q3 24 | 29.8% | 7.0% | ||
| Q2 24 | 30.3% | 10.3% | ||
| Q1 24 | 27.9% | 8.9% |
| Q4 25 | 13.3% | 7.4% | ||
| Q3 25 | 9.0% | 8.0% | ||
| Q2 25 | 17.8% | 6.5% | ||
| Q1 25 | 14.8% | 7.4% | ||
| Q4 24 | 20.4% | 6.6% | ||
| Q3 24 | 21.1% | 5.8% | ||
| Q2 24 | 20.8% | 7.9% | ||
| Q1 24 | 25.1% | 8.1% |
| Q4 25 | $0.51 | $0.83 | ||
| Q3 25 | $0.37 | $0.82 | ||
| Q2 25 | $0.64 | $0.63 | ||
| Q1 25 | $0.51 | $0.73 | ||
| Q4 24 | $0.74 | $0.57 | ||
| Q3 24 | $0.78 | $0.43 | ||
| Q2 24 | $0.73 | $0.55 | ||
| Q1 24 | $0.81 | $0.57 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $15.5M |
| 総負債低いほど良い | $608.7M | $594.0K |
| 株主資本純資産 | $788.8M | $154.5M |
| 総資産 | $1.6B | $295.8M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 0.00× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $15.5M | ||
| Q3 25 | $276.2M | $22.7M | ||
| Q2 25 | $231.8M | $15.3M | ||
| Q1 25 | $236.9M | $13.0M | ||
| Q4 24 | $221.6M | $20.2M | ||
| Q3 24 | $250.5M | $62.3M | ||
| Q2 24 | $217.8M | $62.7M | ||
| Q1 24 | $289.6M | $50.7M |
| Q4 25 | $608.7M | $594.0K | ||
| Q3 25 | $608.6M | $726.0K | ||
| Q2 25 | $607.7M | $796.0K | ||
| Q1 25 | $603.9M | $735.0K | ||
| Q4 24 | $601.6M | $695.0K | ||
| Q3 24 | $596.4M | $802.0K | ||
| Q2 24 | $586.9M | $867.0K | ||
| Q1 24 | $594.0M | $820.0K |
| Q4 25 | $788.8M | $154.5M | ||
| Q3 25 | $776.7M | $143.6M | ||
| Q2 25 | $757.5M | $134.3M | ||
| Q1 25 | $751.3M | $124.2M | ||
| Q4 24 | $732.3M | $108.9M | ||
| Q3 24 | $727.7M | $171.1M | ||
| Q2 24 | $713.3M | $165.8M | ||
| Q1 24 | $672.4M | $159.3M |
| Q4 25 | $1.6B | $295.8M | ||
| Q3 25 | $1.7B | $283.9M | ||
| Q2 25 | $1.6B | $273.2M | ||
| Q1 25 | $1.6B | $274.7M | ||
| Q4 24 | $1.6B | $272.5M | ||
| Q3 24 | $1.5B | $306.3M | ||
| Q2 24 | $1.5B | $293.9M | ||
| Q1 24 | $1.6B | $289.6M |
| Q4 25 | 0.77× | 0.00× | ||
| Q3 25 | 0.78× | 0.01× | ||
| Q2 25 | 0.80× | 0.01× | ||
| Q1 25 | 0.80× | 0.01× | ||
| Q4 24 | 0.82× | 0.01× | ||
| Q3 24 | 0.82× | 0.00× | ||
| Q2 24 | 0.82× | 0.01× | ||
| Q1 24 | 0.88× | 0.01× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $6.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $-5.1M |
| FCFマージンFCF / 売上 | 13.4% | -3.1% |
| 設備投資強度設備投資 / 売上 | 4.5% | 7.1% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 0.54× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $29.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $6.6M | ||
| Q3 25 | $52.6M | $15.7M | ||
| Q2 25 | $35.6M | $27.9M | ||
| Q1 25 | $35.1M | $8.8M | ||
| Q4 24 | $29.0M | $1.1M | ||
| Q3 24 | $60.0M | $7.8M | ||
| Q2 24 | $69.1M | $17.4M | ||
| Q1 24 | $55.3M | $11.4M |
| Q4 25 | $24.6M | $-5.1M | ||
| Q3 25 | $47.2M | $8.0M | ||
| Q2 25 | $25.0M | $22.8M | ||
| Q1 25 | $24.4M | $3.6M | ||
| Q4 24 | $16.6M | $-3.2M | ||
| Q3 24 | $46.2M | $4.1M | ||
| Q2 24 | $63.1M | $15.2M | ||
| Q1 24 | $46.5M | $9.7M |
| Q4 25 | 13.4% | -3.1% | ||
| Q3 25 | 24.6% | 5.3% | ||
| Q2 25 | 14.3% | 15.5% | ||
| Q1 25 | 14.3% | 2.5% | ||
| Q4 24 | 8.9% | -2.3% | ||
| Q3 24 | 24.1% | 3.2% | ||
| Q2 24 | 34.6% | 12.2% | ||
| Q1 24 | 27.1% | 7.7% |
| Q4 25 | 4.5% | 7.1% | ||
| Q3 25 | 2.8% | 5.1% | ||
| Q2 25 | 6.1% | 3.5% | ||
| Q1 25 | 6.3% | 3.7% | ||
| Q4 24 | 6.7% | 3.1% | ||
| Q3 24 | 7.2% | 2.8% | ||
| Q2 24 | 3.3% | 1.8% | ||
| Q1 24 | 5.1% | 1.3% |
| Q4 25 | 1.35× | 0.54× | ||
| Q3 25 | 3.03× | 1.30× | ||
| Q2 25 | 1.15× | 2.91× | ||
| Q1 25 | 1.39× | 0.84× | ||
| Q4 24 | 0.76× | 0.12× | ||
| Q3 24 | 1.48× | 1.03× | ||
| Q2 24 | 1.82× | 1.77× | ||
| Q1 24 | 1.28× | 1.11× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
IBEX
| Transferred Over Time | $147.1M | 90% |
| Transferred At Point In Time | $17.1M | 10% |
